SPECIALTY QUANTITY LIMIT PROGRAM

FASENRA (benralizumab)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization. The recommended dosing parameters for the treatment of severe eosinophilic asthma fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit*	FDA-recommended dosing
Fasenra 30 mg/mL single-dose prefilled syringe/autoinjector	1 syringe per 56 days	3 syringes per 84 days	Initial: 30 mg every 4 weeks for the first 3 doses
, , ,			Maintenance: 30 mg every 8 weeks

*Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

III. REFERENCES

1. Fasenra [package insert]. Wilmington, DE: AstraZeneca; October 2019.

Specialty Quantity Limit Fasenra 2468-H P2019a

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

